Rush University Cancer Center | Strategic Alliance Partners

Ruta D. Rao, MD, discusses factors that inform treatment selection for patients with metastatic HER2-positive breast cancer, the effects key data that emerged in 2021 have had on sequencing, strategies to mitigate toxicities associated with trastuzumab deruxtecan, and remaining questions regarding sequencing that may be the focus of ongoing research effort.

Newer, cheaper and more personalized tests means more people tested and more lives saved.

New findings may lead to novel immunotherapies against third-deadliest cancer.

Timothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.

Ruta Rao, MD, associate professor of medical oncology, Rush University Medical Center, discusses the use of abemaciclib with or without fulvestrant for the treatment of hormone receptor–positive and HER2-negative metastatic breast cancer following prior treatment with palbociclib.

Shikha Jain, MD, hematologist/oncologist, Rush University Medical Center, discusses the disparities between male and female professionals at medical conferences, specifically the American Society of Clinical Oncology (ASCO) Annual Meeting.

Mary J. Fidler, MD, associate professor, Rush University Medical Center, discusses progression-free survival (PFS) and overall survival (OS) in patients with stage IV, nonsquamous, non–small cell lung cancer patients (NSCLC) treated with first-line pemetrexed and platinum followed by pemetrexed maintenance.

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

Melody A. Cobleigh, MD, professor of medical oncology at Rush University Medical Center, discusses antibody–drug conjugates (ADCs) under development in HER2-positive breast cancer.

Although it has been difficult to identify a specific target for triple-negative breast cancer, several therapeutic classes are showing great promise.

Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.

Ruta D. Rao, MD, highlights the importance of determining risk for recurrence and its impact on conversations about extended adjuvant endocrine therapy and the use of chemotherapy in patients with early-stage HR-positive, HER2-negative breast cancer.

Ruta D. Rao, MD, an associate professor at Rush University Medical Center, discusses therapy de-escalation for patients with early-stage hormone receptor (HR)-positive, HER2-negative breast cancer.

Mary Jo Fidler, MD, discusses the latest developments in the treatment of patients with ALK-positive lung cancer.

Ruta D. Rao, MD, elaborates on the findings of the ABCSG-16, SOFT, and TEXT clinical trials and how they have shaped adjuvant treatment for ER-positive breast cancer.

Ruta D. Rao, MD, associate professor, Rush University Medical Center, discusses the results of the SOFT trial, presented at the 2017 San Antonio Breast Cancers Symposium.

Mary Jo Fidler, MD, discusses targeting the EGFR-gene activating mutations, first- and second-generation inhibitors, and the potential of osimertinib.

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non-small cell lung cancer.

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses liquid biopsies in lung cancer.